PPARG and Hyperglycemia: The same effect is obtained with the PPARγ agonist rosiglitazone, which increased PPARγ2 expression level and counteracted the hyperglycemia-induced enhancement of CB1 expression, inflammation, and glomerular fibrosis in diabetic animals.